Anti-ganglioside gd - monoclonal antibody mz, mz-producing cells and mz-containing reagent
CA 1314246 C · Owner: Iwata, Daiji · Inventors: Iwata, Daiji; Sato, Wakao; Shimada, Shizuo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is a novel anti-ganglioside GD1a monoclonal antibody (MZ) which is capable of recognizing ganglioside GD1a but is practically incapable of recognizing GalCer, LacCer, Gb3, Gb4, GA1, GA2 GM1, GM2, GM3, GD1b, GT1b, GQ1b, Fuc-GM1 nLc4 and sialosyl nLc4;, MZ-producing cells; an MZ-containing reagent; and a method for the detection or quantification of GD1a using the reagent, e.g. to diagnose cancer, systematic lupus erythematosus and diseases resulting from organic injury of the nervous system.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted March 9, 1993. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended March 9, 2010.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.